WHAT: Ever read the fine print on the back of the leading household disinfectants? Did you know that today's antimicrobial surface cleaning products have to remain wet on a surface for 10 minutes to kill standard bacteria and do nothing to address resistant strains of bacteria? Did you know that the fine print on the back says they must be rinsed off? Did you know they provide no extended protection? Today's antibacterial products, with kill times of 10 minutes, are not able to compete with the antimicrobial products of the near future. The new generation of products contains an aqueous disinfectant known as Silver Dihydrogen Citrate (SDC). They will begin appearing in retail stores throughout 2006. SDC-based products have bacterial kill times of 30 seconds, (20 times faster than today's household standards), and have the lowest possible level of toxicity as defined by the EPA. SDC-based products also carry 24-hour residual protection, do not require rinsing, do not induce bacterial resistance and are effective as an antibacterial, antiviral and antifungal. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. How does it work? SDC, patented by PURE Bioscience (OTC:PURE) (BULLETIN BOARD: PURE) , is an electrolytically generated source of stabilized ionic silver. The bacteria view SDC as a food source, and once the organism consumes it, SDC destroys the bacteria by disabling proteins and halting its metabolic and reproductive functions. SDC is colorless, odorless, tasteless, non-caustic and formulates well with other compounds. An SDC-based hard surface disinfectant is currently available under the private label Germ Control 24(TM) through a leading online maintenance supply retailer. PURE's distributors plan to launch and market several additional SDC-based disinfecting products throughout 2006. (Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO ) WHO: Michael Krall, CEO of PURE Bioscience is available to speak with the media about the new breed of SDC-based antimicrobial products. Mr. Krall can address the technology of SDC, the widespread number of potential usages, and antimicrobial consumer trends. FOR MORE INFORMATION OR TO SCHEDULE AN INTERVIEW WITH MICHAEL KRALL CONTACT: Karen Kristofferson, (858) 455-5500, About PURE Bioscience PURE Bioscience (PURE) develops and markets technology-based bioscience products that provide non-toxic solutions to numerous global health challenges. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials and boric acid-based pesticides, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. PURE Bioscience, headquartered in El Cajon, California, (San Diego metropolitan area), was incorporated in 1992. For additional information on PURE Bioscience, visit the Company's website: http://www.purebio.com/. This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Media Contact: Investor Contact: Karen Kristofferson, Mentus Terri MacInnis, Bibicoff & Associates, Inc. (858) 455-5500 (818) 379-8500 http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO http://photoarchive.ap.org/ DATASOURCE: PURE Bioscience CONTACT: Media, Karen Kristofferson of Mentus, +1-858-455-5500, , for PURE Bioscience; or Investors, Terri MacInnis of Bibicoff & Associates, Inc., +1-818-379-8500, , for PURE Bioscience Web site: http://www.purebio.com/

Copyright